![]() |
|
Names | |
---|---|
IUPAC name
(2E)-N-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl}-4-(1-piperidinyl)-2-butenamide
|
|
Other names
PF-00299804
|
|
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChemSpider | |
KEGG | |
PubChem CID
|
|
UNII | |
|
|
|
|
Properties | |
C24H25ClFN5O2 | |
Molar mass | 469.95 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
Infobox references | |
Dacomitinib (PF-00299804) is an experimental drug candidate under development by Pfizer for the treatment of non-small-cell lung carcinoma (NSCLC). It is a selective and irreversible inhibitor of EGFR.
Dacomitinib has advanced to several Phase III clinical trials. The Jan 2014 results of the first trials were disappointing, with a failure to meet the study goals, Additional Phase III trials are ongoing.
In 2017 results of a trial comparing dacomitinib to gefitinib for NSCLC (driven by mutated EGFR) were announced.